文章摘要
朱 伟,毛世琴,黄余峰,陈 燕,孔 祥.血浆外泌体miR-1290、miR-1307表达水平与卵巢癌患者临床病理特征的关系及其诊断价值分析[J].,2022,(7):1338-1342
血浆外泌体miR-1290、miR-1307表达水平与卵巢癌患者临床病理特征的关系及其诊断价值分析
Expression Level of Plasma Exosomes miR-1290, miR-1307 in Patients with Ovarian Cancer and their Relationship with Clinicopathological Characteristics and its Diagnostic Value
投稿时间:2021-08-30  修订日期:2021-09-26
DOI:10.13241/j.cnki.pmb.2022.07.030
中文关键词: 血浆  外泌体  卵巢癌  miR-1290  miR-1307  诊断价值
英文关键词: Plasma  Exosomes  Ovarian cancer  miR-1290  miR-1307  Diagnostic value
基金项目:江苏省自然科学基金面上项目(BK20171182)
作者单位E-mail
朱 伟 扬州大学医学院 江苏 扬州 225009靖江市人民医院妇科 江苏 靖江 214500 zhuwei198201@163.com 
毛世琴 靖江市人民医院妇科 江苏 靖江 214500  
黄余峰 靖江市人民医院肿瘤科 江苏 靖江 214500  
陈 燕 靖江市人民医院妇科 江苏 靖江 214500  
孔 祥 苏北人民医院妇产科 江苏 扬州 225001  
摘要点击次数: 482
全文下载次数: 380
中文摘要:
      摘要 目的:探讨卵巢癌患者血浆外泌体中微小RNA(miR)-1290和 miR-1307的表达,分析两者与临床病理参数的关系及诊断价值。方法:选取2019年1月至2021年1月于靖江市人民医院诊治的60例卵巢癌患者为卵巢癌组,另分别选取同期52例良性卵巢肿瘤患者和50例女性健康体检者为良性肿瘤组和健康对照组。采用实时荧光定量PCR(qRT-PCR)法检测miR-1290、miR-1307在各组血浆外泌体中的表达,分析miR-1290、miR-1307与卵巢癌患者临床病理特征的关系,采用受试者工作特征(ROC)曲线分析血浆外泌体miR-1290、miR-1307对卵巢癌的诊断效能。结果:与良性肿瘤组和健康对照组相比,卵巢癌组的血浆外泌体miR-1290、miR-1307表达水平较高(P<0.05)。卵巢癌组的miR-1290表达水平与FIGO分期、分化程度及淋巴结转移有关,miR-1307表达水平与FIGO分期、淋巴结转移有关(P<0.05);卵巢癌患者血浆外泌体miR-1307表达与miR-1290表达呈显著正相关(r=0.478,P<0.05)。血浆外泌体miR-1290、miR-1307联合应用诊断卵巢癌的曲线下面积(AUC)(0.95CI)为0.726(0.526~0.926),高于两指标单独应用的0.724(0.466~0.987)、0.845(0.750~0.933)。结论:卵巢癌患者血浆外泌体miR-1290、miR-1307表达水平升高,两者联合检测对卵巢癌的早期诊断具有较高的价值,有望成为新的卵巢癌的分子标志物。
英文摘要:
      ABSTRACT Objective: To investigate the expression of microRNA (miR)-1290 and mir-1307 in plasma exosomes of patients with ovarian cancer, and to analyze their relationship with clinicopathological parameters and diagnostic value. Methods: 60 patients with ovarian cancer who were diagnosed and treated in Jingjiang People's Hospital from January 2019 to January 2021 were selected as the ovarian cancer group, 50 female health examiners during the same period as the healthy control group and 52 patients with benign ovarian tumors as the benign tumor group. Real-time quantitative PCR (qRT-PCR) was used to detect the expression of miR-1290 and miR-1307 in plasma exosomes of each group. The relationship between miR-1290, miR-1307 and clinicopathological characteristics of patients with ovarian cancer were analyzed. The receiver operating characteristic curve(ROC)was used to analyze the diagnostic efficacy of plasma exosomes miR-1290 and miR-1307 for ovarian cancer. Results: Compared with benign ovarian tumor group and healthy control group, the expression of plasma exosomes miR-1290 and miR-1307 in ovarian cancer group were higher (P<0.05). The expression of miR-1290 in the ovarian cancer group was related to the FIGO stage, degree of differentiation and lymph node metastasis, and the level of miR-1307 was related to the FIGO stage and lymph node metastasis (P<0.05). There was a significant positive correlation between the expression of plasma exosomes miR-1307 and miR-1290 of patients with ovarian cancer (r=0.478, P<0.05). The area under curve (AUC) (0.95CI) of plasma exosomes miR-1290, miR-1307 and combined application in the diagnosis of ovarian cancer were 0.726 (0.526 ~ 0.926), 0.724 (0.466 ~ 0.987) and 0.845 (0.750 ~ 0.933), respectively. The diagnostic efficiency of combined application was higher than that of single application. Conclusion: The expression levels of plasma exosomes miR-1290 and miR-1307 in patients with ovarian cancer are increased. The combined detection of miR-1290 and miR-1307 has high value in the early diagnosis of ovarian cancer, and is expected to become a new molecular marker of ovarian cancer.
查看全文   查看/发表评论  下载PDF阅读器
关闭